An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate

Abstract Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus. Further, each form of tenofovir requires laboratory monitoring to determine efficacy a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Derek E. Murrell, Benjamin C. Kennard, Maria E. Bertoni, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Kesheng Wang, Michelle M. Duffourc, Sam Harirforoosh
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-05-01
Series:	Drugs in R&D
Online Access:	https://doi.org/10.1007/s40268-025-00509-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01)

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
by: Hamed Mirmoezzi, et al.
Published: (2025-03-01)

Comparative effectiveness and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in patients with HBV-associated decompensated cirrhosis: insights from a retrospective analysis
by: Lu Chen, et al.
Published: (2025-08-01)

Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.
by: Yi Lin, et al.
Published: (2025-01-01)

Tenofovir disoproxil fumarate for preventing mother-to-child transmission of hepatitis B: a literature review
by: Iulia Baciu, et al.
Published: (2021-02-01)

Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
by: Bruno Emond, et al.
Published: (2022-02-01)

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
by: Hyung Joon Yim, et al.
Published: (2025-07-01)

Effect of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamideantiviral Therapy on Renal Function in Chronic Hepatitis B Patients: A Real-World Retrospective Study
by: Li Y, et al.
Published: (2025-02-01)

Factors Affecting Rapid Decline in Glomerular Filtration Rate in HIV/AIDS Patients Using Tenofovir Disoproxil Fumarate
by: Prima Yuriandro, et al.
Published: (2019-09-01)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
by: Josep M Llibre, et al.
Published: (2016-01-01)

Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
by: Freeman W Chabala, et al.
Published: (2021-01-01)

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis
by: Tegene Legese Dadi, et al.
Published: (2017-01-01)

Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China
by: Aixin Li, et al.
Published: (2025-05-01)

Cost-effectiveness of tenofovir disoproxil fumarate prophylaxis for perinatal hepatitis B virus prevention in Ethiopia: a decision analytical modeling
by: Abdi Gari Negasa, et al.
Published: (2025-04-01)

Evaluation of Hippocampal Microanatomy and Neuro-Biomarkers Following Administration of Silver Nanoparticles Conjugated with Tenofovir Disoproxil Fumarate in Experimental Diabetic Rats
by: Sodiq Kolawole Lawal, et al.
Published: (2024-12-01)

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks
by: Willington Amutuhaire, et al.
Published: (2025-01-01)

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.
by: Willington Amutuhaire, et al.
Published: (2025-01-01)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-10-01)

Efficacy of Tenofovir Disoproxil Fumarate in Preventing Vertical Transmission of Hepatitis B in Mothers with Chronic Hepatitis B: An Evidence-Based Case Report
by: Ris Raihan Felim, et al.
Published: (2024-07-01)

Modulation and distribution of extracellular free water and tract deficits in rhesus macaques before and after the initiation of emtricitabine + tenofovir disoproxil fumarate + dotutegravir treatment
by: Benedictor Alexander Nguchu, et al.
Published: (2025-02-01)

Reduced Kidney Function in Tenofovir Disoproxil Fumarate Based Regimen and Associated Factors: A Hospital Based Prospective Observational Study in Ethiopian Patients
by: Taklo Simeneh Yazie, et al.
Published: (2019-01-01)

Simple Spectrophotometric Methods for Determination of Tenofovir Fumarate and Emtricitabine in Bulk Powder and in Tablets
by: Mohammad H. AbdelHay, et al.
Published: (2013-01-01)

Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
by: Lu Wang, et al.
Published: (2021-08-01)

Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis
by: Yong Wang, et al.
Published: (2025-05-01)

Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)
by: Roberta Gagliardini, et al.
Published: (2025-09-01)

The Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations
by: Omobolanle Ayoyinka Omoteso, et al.
Published: (2022-01-01)

Factors predicting renal impairment associated with Tenofovir Disoproxil fumarate: Focus on patients with HIV and pre-existing metabolic abnormalities under the Thai National Health Security Scheme
by: Duangjai Duangrithi, et al.
Published: (2025-08-01)

Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial
by: Jun Chen, et al.
Published: (2020-01-01)

Hepatitis surface B antigen clearance induced by long-term tenofovir disoproxil fumarate monotherapy in chronic hepatitis B treatment: a meta-analysis and longitudinal modeling analysis
by: Weizhe Jian, et al.
Published: (2025-05-01)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.
by: Nicola Squillace, et al.
Published: (2017-01-01)

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
by: Elise Chia-Hui Tan, et al.
Published: (2025-03-01)

Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study
by: Xinye Qiu, et al.
Published: (2025-04-01)

Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
by: Eric S. Daar, et al.
Published: (2025-04-01)

A cross‐sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV‐1 in tenofovir disoproxil fumarate‐based pre‐exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa
by: Urvi M. Parikh, et al.
Published: (2025-08-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01)

Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
by: Takuya Matsubara, et al.
Published: (2025-01-01)

Characterizing treatment interruptions in the OPERA cohort and virologic outcomes after resumption with bictegravir/emtricitabine/tenofovir alafenamide
by: Karam Mounzer, et al.
Published: (2025-07-01)